Bessemer Group
KERX

Bessemer Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Bessemer Group’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,355
Closed -$11K – 1538
2016
Q1 		$11K Buy
2,355
+355
+18% +$1.42K ﹤0.01% 1140
2015
Q4 		$10K Sell
2,000
-329
-14% -$1.56K ﹤0.01% 1235
2015
Q3 		$8K Sell
2,329
-292
-11% -$1.96K ﹤0.01% 1260
2015
Q2 		$26K Buy
2,621
+290
+12% +$3.11K ﹤0.01% 1094
2015
Q1 		$29K Sell
2,331
-14
-0.6% -$180 ﹤0.01% 1075
2014
Q4 		$33K Hold
2,345
– – ﹤0.01% 1022
2014
Q3 		$33K Buy
2,345
+2,116
+924% +$32.4K ﹤0.01% 946
2014
Q2 		$4K Hold
229
– – ﹤0.01% 1202
2014
Q1 		$4K Buy
+229
New +$3.46K ﹤0.01% 1206

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bessemer Group's KERX Position: Q2 2016 in Review

Bessemer Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2016, closing a stake of 2,355 shares — an estimated $11K sold.

Bessemer Group first reported a position in KERX in Q1 2014 and held it in 9 quarters. The position peaked at $33K in Q4 2014. 118 funds tracked by Wall St. Rank hold KERX as of Q2 2016.

  • Bessemer Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Bessemer Group sold 2,355 Keryx Biopharmaceuticals Inc shares in Q2 2016, an estimated $11K.
  • Bessemer Group first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and held it in 9 quarters.
  • Bessemer Group's Keryx Biopharmaceuticals Inc position peaked at $33K in Q4 2014.
  • 118 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2016.

Based on Bessemer Group's 13F filing for Q2 2016, filed 11 Aug 2016.